ArticlePloS one2012
Circulating DNA: diagnostic tool and predictive marker for overall survival of NSCLC patients.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer.Oncotarget · 2016Pooled it
- Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non-small Cell Lung Cancer in the Global Phase III ALEX Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Trial
- Quantifying circulating cell-free DNA in humans.Scientific reports · 2019Trial
- Longitudinal cell-free DNA methylome and fragmentome profiles in health uncover signatures of cell type and demographic origin.Genome medicine · 2026Article
- Clinical applications of circulating biomarkers in non-small cell lung cancer.Frontiers in cell and developmental biology · 2024Review
- Liquid Biopsy in NSCLC: An Investigation with Multiple Clinical Implications.International journal of molecular sciences · 2023Review
- Quantitative analysis of serum cell-free DNA as a predictive and prognostic marker in breast cancer patients.Frontiers in oncology · 2023Article
- Diagnosis, Monitoring, and Prognosis of Liquid Biopsy in Cancer Immunotherapy.Methods in molecular biology (Clifton, N.J.) · 2023Review
- A systematic review and meta-analysis of circulating cell-free DNA as a diagnostic biomarker for non-small cell lung cancer.Journal of thoracic disease · 2022Article
- Using All Our Genomes: Blood-based Liquid Biopsies for the Early Detection of Cancer.View (Beijing, China) · 2022Article
- The influence of biological and lifestyle factors on circulating cell-free DNA in blood plasma.eLife · 2021Review
- Liquid Biopsy Biomarkers for Immunotherapy in Non-Small Cell Lung Carcinoma: Lessons Learned and the Road Ahead.Journal of personalized medicine · 2021Review
- The prognostic value of longitudinal circulating tumor DNA profiling during osimertinib treatment.Translational lung cancer research · 2021Article
- The Potential Use of Dynamics Changes of ctDNA and cfDNA in the Perioperative Period to Predict the Recurrence Risk in Early NSCLC.Frontiers in oncology · 2021Article
- The Role of Liquid Biopsy in Early Diagnosis of Lung Cancer.Frontiers in oncology · 2021Review
- Simultaneous Isolation of Circulating Nucleic Acids and EV-Associated Protein Biomarkers From Unprocessed Plasma Using an AC Electrokinetics-Based Platform.Frontiers in bioengineering and biotechnology · 2020Article
- Saliva-derived cfDNA is applicable for EGFR mutation detection but not for quantitation analysis in non-small cell lung cancer.Thoracic cancer · 2019Article
- The emerging role of cell-free DNA as a molecular marker for cancer management.Biomolecular detection and quantification · 2019Review
- Circulating cell-free DNA does not harbour a diagnostic benefit in cats with feline diffuse iris melanomas.Journal of feline medicine and surgery · 2019Article
- Clinical applications of liquid biopsies for early lung cancer detection.American journal of cancer research · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe purpose of our study was to determine whether the amounts of circulating DNA (cDNA) could discriminate between NSCLC patients and healthy individuals and assess its value as a prognostic marker of this disease.
methodsWe conducted a study of 309 individuals and the cDNA levels were assessed through real-time PCR methodology.
resultsWe found increased cDNA levels in NSCLC patients compared to control individuals. We also found a decreased overall survival time in patients presenting high cDNA levels, when compared to lower cDNA concentrations.
conclusionsQuantification of cDNA may be a good tool for NSCLC detection with potential for clinical applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.